תעשיית תרופות המקור בישראל 2014

  • View
    236

  • Download
    13

Embed Size (px)

DESCRIPTION

2014 : , ,

Transcript

  • 4102

    -noitaN amrahP

  • 2

  • .

    , . , : - -006,1 , , , ; - , , , ; - ,

    .

    , . %2 , %6 . , -.

    .

    :

    :

    , :

    - - %01 56 (-008 ), . , , 56 . , ,

    .

    - , . , , , -%57

    . - , , , - . , , ,

    . , , : -5.1 , -51-01 , 000,5:1. , , ,

    , .

    , , , , - ,

    .

    , ,

    .

    3

  • , . , ,

    .

    . , ,

    .

    , .

    , .

    .

    , , .

    4

  • ,

    , .

    4102 -noitaN amrahP, : , , .

    , .

    , , , . . , , , , .

    .

    . , .

    . . : , , , , .

    . 02 . , . , . , , ,

    .

    , ,

    ,

    5

  • 6

  • 32-81

    - 72-42

    71-01

    -noitaN amrahP 33-82

    7

  • . , , , . , , ,

    . . . , -%6 . , ., ,

    , . . , , ; , , ; , ; , .

    : -5.1

    : 51-01

    : 000,5:1

    )IOR - tnemtsevnI nO nruteR(: 3:1

    , , ,

    .

    : -000,3

    : -006,1

    -001 ,

    , :

    8

  • .

    - , , , ; , . , , . , . , , . , ,

    - . ,

    .

    . , , . , . . , , noitaN-amrahP.

    , . . ,

    - , , . , , -noitaN-amrahP.

    - :

    , ,

    ,

    ,

    , ,

    , ,

    - :

    , ,

    :

    ,

    ecnaligivocamrahp

    -

    :

    -

    - , ,

    ,

    ,

    -

    , ,

    -

    ,

    - %57! , %07

    , -%84 !

    noitaN-amrahP

    9

  • 1

  • ,

    , .

    , , .

    .

    . .

    , . , -%04. . , -%85

    -%08 .[7]

    %54 9991 -5002

    4102 ,muilisnoC-hctaguP :sisylanA ;7002 ,.lA te xoF .A.K :ecruoS

    -

    -

    -

    %52

    %02

    %51

    %01

    %5

    %0%2

    %08.4

    %04.8

    %06.4

    %11

    %05.91

    9991

    5002

    4102 ,muilisnoC-hctaguP :sisylanA ;eraC rof snoitacilpmI dna yrotcejarT pihsrovivruS ehT ssorcA ecnelaverP :setatS detinU ehT nI srovivruS recnaC .)3102( .lA te .S .J ,rooM eD :ecruoS

    01

    21

    41

    61

    81

    02

    8

    6

    4

    2

    02202 7102 2102 7002 2002 7991 2991 7891 2891 7791

    51

    01 - 51

    5 - 01

    - 5

    11

  • . , - . , - , -PDOC

    .

    . , -5.2 [51]. - , ,

    .[2]

    . -%37 8. -, , : -%08

    -09, , , .[01] , , ( ) ,

    .[11]

    ? 72.1 !

    21

  • 1

    )%(

    %99

  • . , , .

    -000,007 , .[3] 4-3 .

    , *

    ;3102 ,elfiorP yrtsudnI hcraeseR lacituecamrahpoiB ,AMRhP ;3102 ,serugiF ni yrtsudnI lacituecamrahP ehT ,AIPFE :ecruoS, - : ,11024102 ,muilisnoC-hctaguP :sisylanA

    0000061 0000041 0000021 0000001 000008 000006 000004 000002 0

    000,018

    000,095

    000,611

    005,21

    000,53

    000,07

    000,000,1

    000,001,1

    000,005,1

    1

    2 ,

    , ,

    3 ,

    ,

    41

  • . , , (snitats), . () ,

    . . ;

    -DCEO .[31,4] , , , , . , .[9] , .[41,5]

    1

    4102 ,muilisnoC-hctaguP :sisylanA ;3102 ,elfiorP yrtsudnI hcraeseR lacituecamrahpoiB ,AMRhP :ecruoS

    307,3 692,2 401,2

    205,1

    015,6-

    644,51-

    035,51-

    480,13-

    000,01

    000,5

    0

    000,5-

    000,01-

    000,51-

    000,02-

    000,52-

    000,03-

    000,53-

    -

    .

    -04 , , . , , ; , ,

    .[21]

    .

    : . - - ,

    -.

    *

    51

  • .

    , , , , , ,

    .

    .

    , - , . , , - , . , , .

    ? , )-%08( . 000,5 -000,7 .

    .

    , . ,

    , . ,

    , .

    ? , )sesaesiD laciporT dna detcelgeN(,

    , , . : )VIH(, . 71 ,

    . . [61] ,

    .

    AND

    - -000,000,51 " ,

    ,

    -000,000,054 " *

    -000,3

    -006,1

    -001 ,

    000,001

    -005,21

    005,21-000,001

    %57 -

    %57

    %77 %77

    *

    %07

    %84

    61

  • 1

    :

    1. .109-110 ' , : , .)2010( ,

    2. Canadian Public Health Association, (2001). The Value of Immunization in The Future of Canadas Health System.

    3. EFPIA, (2013). The Pharmaceutical Industry In Figures: Key Data, Belgium: EFPIA, p. 13

    4. Healy, P. (2011). Which Price is Right? Regulating the Cost of Pharmaceuticals in Europe and North America, The Stockholm Network, p. 4.

    5. Hermus, G. et Al. (2013). Reducing the Health Care and Societal Costs of Disease: The Role of Pharmaceuticals, The Conference Board of Canada Report.

    6. IFPMA, (2004). The Pharmaceutical Innovation Platform, Geneva, Switzerland, p. 17.

    7. Innovation.org, Saving and Improving Lives, Extending Lives.

    http://www.innovation.org/index.cfm/impactofinnovation/Saving&ImprovingLives#vii, Accessed 30.4.2014.

    8. Lichtenberg, F. R. (2013). Pharmaceutical Innovation and Longevity Growth In 30 Developing and High-Income Countries, 2000-2009, Health Policy and Technology, p. 11.

    9. Lichtenberg, F.R. (2013). The impact of pharmaceutical innovation on disability days and the use of medical services in the United States, 1997-2010, Columbia University and The National Bureau of Economic Research.

    10. PhRMA, (2012). Innovative Medicines Help Turn HIV Infection Into Chronic Disease,

    http://www.phrma.org/media/releases/innovative-medicines-help-turn-hiv-infection-chronic-disease.

    11. PhRMA, (2013). Rare Diseases: A Report On Orphan Drugs In The Pipeline. http://www.phrma.org/sites/default/files/pdf/Rare_Diseases_2013.pdf

    12. Pugatch Consilium, (2012). Assembling The Pharmaceutical R&D Puzzle for Needs In The Developing World, p. 19.

    13. Pugatch, M. P., Healy, P., Chu, R. (2010). Sharing The Burden: Could Risk-Sharing Change The Way We Pay For Healthcare?, The Stockholm Network, pp. 11-12;

    14. Santerre, R. (2011). National and International Tests of The New Drug Cost Offset Theory, Southern Economic Journal, Vol. 77, No. 4, pp. 1037-1040;

    15. WHO, UNICEF, World Bank, (2009). State of The World Vaccines and Immunization, 3rd Ed, Geneva: World Health Organization, p. 4.

    16. Ibid, note 12, pp 14-15

    17

  • 2

  • , , ,

    . - -

    .

    -: 3 -6 . , -052 - .[7] , ,

    %02.[1]

    : , , . 5 -7 , -%06, -%61. , 5 052

    , ; , , (tnemtsevnI nO nruteR)

    -%03.[11]

    -, :

    .

    , - , , ; , ,

    , . - (000,5-000,1 ) , -

    .[11,9]

    -

    ( VI)

    91

    %5.12

    %9.65

    %3.8%8.9

    %5.3

    .8%7

    1

    5.2 %

    %7.53